Legal Representation
Attorney
R. Neil Sudol
USPTO Deadlines
Application History
40 eventsDate | Code | Type | Description | Documents |
---|---|---|---|---|
Dec 12, 2022 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
Dec 12, 2022 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
Apr 26, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Apr 25, 2022 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
Apr 25, 2022 | EX5G | S | SOU EXTENSION 5 GRANTED | Loading... |
Apr 20, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Apr 20, 2022 | EXT5 | S | SOU EXTENSION 5 FILED | Loading... |
Jan 18, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Nov 6, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Nov 4, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Nov 4, 2021 | EXT4 | S | SOU EXTENSION 4 FILED | Loading... |
Nov 4, 2021 | EX4G | S | SOU EXTENSION 4 GRANTED | Loading... |
Apr 28, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Apr 26, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Apr 26, 2021 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
Apr 26, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
Oct 31, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Oct 29, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Oct 29, 2020 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
Oct 29, 2020 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
May 1, 2020 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Apr 21, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
Apr 17, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
Apr 17, 2020 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
Apr 17, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
Nov 5, 2019 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
Sep 10, 2019 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
Sep 10, 2019 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
Aug 21, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
Aug 4, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
Jul 29, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
Jul 29, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
Jul 23, 2019 | ALIE | A | ASSIGNED TO LIE | Loading... |
Jul 18, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
Jan 22, 2019 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
Jan 22, 2019 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
Jan 22, 2019 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
Jan 15, 2019 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
Oct 12, 2018 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
Oct 6, 2018 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of lipids, containing and facilitating the delivery of pharmaceuticals for the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), ankylosing spondylitis; vaccines and vaccinations to prevent or treat infectious diseases and cancer; drug delivery agents in the form of capsules made of cholesteryl ester, containing and facilitating the delivery of pharmaceuticals for use in the treatment of Alzheimer's disease, Parkinson's disease, bacterial infections, viral infections, fungal infections, sepsis, psoriasis, sunburn and thermal injury to skin and underlying tissues, lung disease, asthma, chronic obstructive pulmonary disease (COPD), emphysema, cancer of all types, diabetes, hepatic diseases including hepatitis b or c, hepatic disease including non- alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), metabolic syndrome diseases, genetic disorders, Fabry's disease, alpha 1 anti-trypsin deficiency, hemophilia, cystic fibrosis, systemic inflammatory diseases including inflammatory bowel diseases, Crohn's disease, rheumatoid arthritis, Systemic lupus erythematosus (SLE), and ankylosing spondylitis; and vaccines and vaccinations to prevent or treat infectious diseases and cancer
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005